These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25265335)

  • 21. BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1).
    Jones PH; Maric M; Madison MN; Maury W; Roller RJ; Okeoma CM
    Virology; 2013 Mar; 438(1):37-49. PubMed ID: 23411007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells.
    Metz SW; Pijlman GP
    Methods Mol Biol; 2016; 1426():297-309. PubMed ID: 27233282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of chikungunya Virus-Like Particles and Pseudotyped-Particles used for serological detection of specific immunoglobulin M.
    Theillet G; Martinez J; Steinbrugger C; Lavillette D; Coutard B; Papageorgiou N; Dalbon P; Leparc-Goffart I; Bedin F
    Virology; 2019 Mar; 529():195-204. PubMed ID: 30721816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™.
    Pedraza-Escalona M; Guzmán-Bringas O; Arrieta-Oliva HI; Gómez-Castellano K; Salinas-Trujano J; Torres-Flores J; Muñoz-Herrera JC; Camacho-Sandoval R; Contreras-Pineda P; Chacón-Salinas R; Pérez-Tapia SM; Almagro JC
    BMC Infect Dis; 2021 Oct; 21(1):1121. PubMed ID: 34717584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
    Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
    J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
    Selvarajah S; Sexton NR; Kahle KM; Fong RH; Mattia KA; Gardner J; Lu K; Liss NM; Salvador B; Tucker DF; Barnes T; Mabila M; Zhou X; Rossini G; Rucker JB; Sanders DA; Suhrbier A; Sambri V; Michault A; Muench MO; Doranz BJ; Simmons G
    PLoS Negl Trop Dis; 2013; 7(9):e2423. PubMed ID: 24069479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
    Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
    J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection and characterization of protective anti-chikungunya virus single domain antibodies.
    Liu JL; Shriver-Lake LC; Zabetakis D; Anderson GP; Goldman ER
    Mol Immunol; 2019 Jan; 105():190-197. PubMed ID: 30550981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India.
    Verma A; Nayak K; Chandele A; Singla M; Ratageri VH; Lodha R; Kabra SK; Murali-Krishna K; Ray P
    Arch Virol; 2021 Jul; 166(7):1913-1920. PubMed ID: 33907861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells.
    Metz SW; Geertsema C; Martina BE; Andrade P; Heldens JG; van Oers MM; Goldbach RW; Vlak JM; Pijlman GP
    Virol J; 2011 Jul; 8():353. PubMed ID: 21762510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective chikungunya virus-like particle vaccine produced in insect cells.
    Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
    PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
    MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.
    Lee CY; Kam YW; Fric J; Malleret B; Koh EG; Prakash C; Huang W; Lee WW; Lin C; Lin RT; Renia L; Wang CI; Ng LF; Warter L
    PLoS Pathog; 2011 Dec; 7(12):e1002390. PubMed ID: 22144891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.
    Akahata W; Yang ZY; Andersen H; Sun S; Holdaway HA; Kong WP; Lewis MG; Higgs S; Rossmann MG; Rao S; Nabel GJ
    Nat Med; 2010 Mar; 16(3):334-8. PubMed ID: 20111039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and evaluation of Chikungunya virus E1 and E2 envelope proteins for serodiagnosis of Chikungunya virus infection.
    Cho B; Jeon BY; Kim J; Noh J; Kim J; Park M; Park S
    Yonsei Med J; 2008 Oct; 49(5):828-35. PubMed ID: 18972604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative evaluation of the diagnostic potential of recombinant envelope proteins and native cell culture purified viral antigens of Chikungunya virus.
    Khan M; Dhanwani R; Kumar JS; Rao PV; Parida M
    J Med Virol; 2014 Jul; 86(7):1169-75. PubMed ID: 24105844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
    Weber C; Büchner SM; Schnierle BS
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of N-glycosylation profiles from mammalian and insect cell derived chikungunya VLP.
    Lancaster C; Pristatsky P; Hoang VM; Casimiro DR; Schwartz RM; Rustandi R; Ha S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():218-223. PubMed ID: 27157808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization.
    Sun S; Xiang Y; Akahata W; Holdaway H; Pal P; Zhang X; Diamond MS; Nabel GJ; Rossmann MG
    Elife; 2013 Apr; 2():e00435. PubMed ID: 23577234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.
    Henss L; Yue C; Von Rhein C; Tschismarov R; Lewis-Ximenez LL; Dölle A; Baylis SA; Schnierle BS
    J Infect Dis; 2020 Apr; 221(10):1713-1723. PubMed ID: 31828322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.